A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
- Conditions
- Mycobacterium Avium-Intracellulare InfectionHIV Infections
- Registration Number
- NCT00002101
- Lead Sponsor
- Pharmacia
- Brief Summary
To compare the efficacy of clarithromycin/ethambutol with placebo or with rifabutin at two different doses in reducing colony-forming units (CFUs) by 2 or more logarithms in patients with Mycobacterium avium Complex bacteremia and maintaining this response until 16 weeks post-randomization. To assess survival and comparative tolerability among the three treatment regimens.
- Detailed Description
Patients are randomized to receive clarithromycin and ethambutol plus either placebo or rifabutin at one of two doses. Treatment continues indefinitely. AS PER AMENDMENT 04/19/94: Doses of rifabutin have been lowered.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 450
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (43)
McDowell Clinic
🇺🇸Phoenix, Arizona, United States
Maricopa Med Research Foundation
🇺🇸Phoenix, Arizona, United States
Bay Harbor Hosp
🇺🇸Harbor City, California, United States
Ctr for Special Immunology
🇺🇸Miami Beach, Florida, United States
Combat Group
🇺🇸Los Angeles, California, United States
Cedars Sinai Med Ctr
🇺🇸Los Angeles, California, United States
Highland Gen Hosp / San Francisco Gen Hosp
🇺🇸Oakland, California, United States
HIV Research Group
🇺🇸San Diego, California, United States
UCSD / Ctr for Special Immunology
🇺🇸San Diego, California, United States
Saint Francis Mem Hosp
🇺🇸San Francisco, California, United States
Scroll for more (33 remaining)McDowell Clinic🇺🇸Phoenix, Arizona, United States